InMed expects Mentari merger to close Nov. 6
INM•InMed Pharmaceuticals expects its merger with Mentari Therapeutics to close Nov. 6, 2026, subject to remaining closing conditions. The combined company expects to begin Nasdaq trading as Mentari Therapeutics under ticker MTRI on Nov. 9.
1. Merger timeline
InMed Pharmaceuticals expects its merger with Mentari Therapeutics to close on Nov. 6, 2026, subject to satisfaction or waiver of remaining closing conditions. The combined company expects to begin Nasdaq trading as Mentari Therapeutics under ticker MTRI on Nov. 9.
2. Contingent value rights
Shareholders of record on Nov. 5 are expected to receive one contingent value right per common share, reflecting a one-for-ten share consolidation. Each right provides potential payments tied to specified events under the merger-related agreement.
